These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 11355274)
61. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Hashiguchi M; Ohno K; Saito R Yakugaku Zasshi; 2004 Jun; 124(6):321-32. PubMed ID: 15170067 [TBL] [Abstract][Full Text] [Related]
62. Pharmacotherapy of intermittent claudication. Doggrell SA Expert Opin Pharmacother; 2001 Nov; 2(11):1725-36. PubMed ID: 11825312 [TBL] [Abstract][Full Text] [Related]
63. Management of peripheral arterial disease in the elderly: focus on cilostazol. Falconer TM; Eikelboom JW; Hankey GJ; Norman PE Clin Interv Aging; 2008; 3(1):17-23. PubMed ID: 18488875 [TBL] [Abstract][Full Text] [Related]
64. A randomized trial of iloprost in patients with intermittent claudication. Creager MA; Pande RL; Hiatt WR Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433 [TBL] [Abstract][Full Text] [Related]
65. Intermittent claudication: effective medical management of a common circulatory problem. Beebe HG Am J Cardiol; 2001 Jun; 87(12A):14D-18D. PubMed ID: 11434895 [TBL] [Abstract][Full Text] [Related]
66. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195 [TBL] [Abstract][Full Text] [Related]
67. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial. Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; De Sanctis MT; Incandela L; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Bavera P; Ippolito E Angiology; 2002; 53 Suppl 1():S1-5. PubMed ID: 11865828 [TBL] [Abstract][Full Text] [Related]
68. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370 [TBL] [Abstract][Full Text] [Related]
69. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Pande RL; Hiatt WR; Zhang P; Hittel N; Creager MA Vasc Med; 2010 Jun; 15(3):181-8. PubMed ID: 20385711 [TBL] [Abstract][Full Text] [Related]
70. Cilostazol and outcome in outpatients with peripheral artery disease. Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M; Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338 [TBL] [Abstract][Full Text] [Related]
71. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial--walking distance and microcirculation. De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Incandela L; Bucci M; Geroulakos G; Ramaswami G; Vasdekis S; Agus G; Bavera P; Ippolito E Angiology; 2002; 53 Suppl 1():S7-12. PubMed ID: 11865838 [TBL] [Abstract][Full Text] [Related]
73. Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Mohler ER; Beebe HG; Salles-Cuhna S; Zimet R; Zhang P; Heckman J; Forbes WP Vasc Med; 2001; 6(3):151-6. PubMed ID: 11789969 [TBL] [Abstract][Full Text] [Related]
74. [Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol]. Rosa MP; Baroni GV; Portal VL Arq Bras Endocrinol Metabol; 2007 Dec; 51(9):1528-32. PubMed ID: 18209897 [TBL] [Abstract][Full Text] [Related]
75. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Reich T; Cutler BC; Lee BY; Porter JM; Reichle FA; Scogin JT; Strandness DE Angiology; 1984 Jul; 35(7):389-95. PubMed ID: 6380347 [TBL] [Abstract][Full Text] [Related]
76. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Lewis RJ; Connor JT; Teerlink JR; Murphy JR; Cooper LT; Hiatt WR; Brass EP Trials; 2011 May; 12():134. PubMed ID: 21612611 [TBL] [Abstract][Full Text] [Related]
77. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial. Peters H; Kieser M; Hölscher U Vasa; 1998 May; 27(2):106-10. PubMed ID: 9612115 [TBL] [Abstract][Full Text] [Related]
78. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. Cleanthis M; Bhattacharya V; Smout J; Ashour H; Stansby G Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212 [TBL] [Abstract][Full Text] [Related]
79. Cilostazol: a replacement for pentoxifylline? Shukla V Issues Emerg Health Technol; 1999 Jul; (7):1-4. PubMed ID: 11811214 [No Abstract] [Full Text] [Related]
80. Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes. Huisinga JM; Pipinos II; Stergiou N; Johanning JM J Appl Biomech; 2010 Aug; 26(3):341-8. PubMed ID: 20841626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]